It is widely believed that the path to early and effective treatment for Alzheimer's disease
(AD) requires the development of early diagnostic markers that are both sensitive and …

The main goal of our studies has been to use MRI, FDG‐PET, and CSF biomarkers to
identify in cognitively normal elderly (NL) subjects and in patients with mild cognitive …

The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit
from biomarkers that are sensitive to the subtle brain changes that occur in the preclinical …

The diagnosis of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI)
is limited because it is based on non-specific behavioral and neuroimaging findings. The …

Neuroimaging is being increasingly used to complement clinical assessments in the early
detection of Alzheimer's disease (AD). Structural magnetic resonance imaging (MRI) and …

Several neuroimaging techniques are promising tools as early markers of brain pathology in
Alzheimer's disease (AD). On structural MRI, atrophy of the entorhinal cortex is present …

The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit
from biomarkers that are sensitive to subtle brain changes occurring in the preclinical stage …

The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD),
with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review …

Alzheimer's disease (AD) starts at a molecular level possibly decades earlier than could be
detected by neuropsychological tests (NPTs). Neuropathological and neuroimaging data …

BackgroundAbnormal levels of biomarkers in cerebrospinal fluid (CSF) and atrophy of
medial temporal lobe (MTL) structures on magnetic resonance imaging (MRI) are being …